About
Paradromics is a neurotechnology company building an advanced brain-computer interface (BCI) platform designed to unlock breakthrough healthcare applications for patients with severe neurological conditions. At the core of their technology is single-neuron recording capability—capturing brain activity at the individual neuron level—paired with machine learning algorithms that translate complex neural signals into actionable health data and digital outputs. Their flagship product, Connexus® BCI, aims to restore independent communication for individuals who have lost the ability to speak due to ALS, spinal cord injuries, or stroke, enabling seamless interaction with digital devices through thought alone. The platform supports 1,600+ intracortical channels by linking up to four implants, each smaller than a dime, and is engineered from proven materials for long-term implantable use. Paradromics has received FDA approval to conduct the Connexus BCI Clinical Study. The pipeline product Tempo™ targets mental health applications through continuous brain-state monitoring, with ambitions to address conditions such as chronic pain, addiction, and depression. The platform's scalable, software-driven architecture means the same core AI models and hardware can be adapted to process the most expansive brain-activity datasets in existence. Paradromics is positioned at the frontier of medical neurotechnology, combining industry-leading data rates with AI-powered signal interpretation to enable next-generation clinical applications that were previously impossible.
Key Features
- Single-Neuron Resolution Recording: Records brain activity at the highest possible resolution—individual neurons—providing unmatched data fidelity compared to conventional BCI systems.
- Advanced AI Signal Decoding: Machine learning algorithms translate massive volumes of neural activity data into actionable outputs, enabling the seamless conversion of thought into communication or treatment.
- High-Bandwidth Scalable Platform: Supports 1,600+ intracortical channels by linking up to four implants, offering industry-leading data rates for complex digital communication tasks.
- Long-Term Implantable Design: Built from proven biocompatible materials in a fully implantable form factor engineered for durable, long-term use in clinical environments.
- Multi-Condition Pipeline: The same platform architecture supports diverse applications from communication restoration (Connexus®) to mental health brain-state monitoring (Tempo™).
Use Cases
- Restoring independent speech and communication for ALS patients who have lost the ability to speak
- Enabling digital device control through thought for individuals with complete spinal cord injuries
- Continuous brain-state monitoring to support personalized mental health treatments for depression and addiction
- Neuroscience research leveraging high-resolution, single-neuron brain activity datasets
- Developing closed-loop neural therapies for chronic pain and movement disorders
Pros
- Highest-Resolution BCI Available: Single-neuron recording capability provides a level of brain data quality that enables more precise and complex decoding than competing BCI platforms.
- FDA-Approved Clinical Study: Regulatory clearance for the Connexus BCI Clinical Study is a significant validation of the device's safety profile and clinical potential.
- Broad Application Potential: A single scalable platform designed to address multiple unmet medical needs—paralysis, mental health, chronic pain, and movement disorders—amplifies long-term impact.
Cons
- Not Yet Commercially Available: Connexus® BCI is currently an investigational device and is not approved for sale in the United States, limiting access to clinical trial participants only.
- Requires Invasive Surgical Implantation: As a fully implantable device, the system requires neurosurgical procedures, which restricts the patient population and increases clinical complexity.
- Early-Stage Pipeline Products: Tempo™ and other future applications remain in the pipeline phase, with no confirmed timelines for clinical availability.
Frequently Asked Questions
What is the Connexus® BCI?
Connexus® is Paradromics' first brain-computer interface product designed to help people who cannot speak due to ALS, spinal cord injuries, or stroke communicate independently through digital devices by decoding their neural signals.
Is the Connexus BCI available for purchase?
No. Connexus® BCI is currently an investigational device and is not available for sale in the United States. It is being evaluated through an FDA-approved clinical study.
How does Paradromics' AI work?
Paradromics uses machine learning algorithms to process large volumes of neural activity data recorded at single-neuron resolution. These algorithms decode patterns of brain activity and translate them into digital commands or health insights.
What is Tempo™?
Tempo™ is Paradromics' pipeline BCI product focused on mental health applications. It is designed to monitor brain states continuously, with potential use in treating conditions such as depression, addiction, and chronic pain.
Who is Paradromics' technology designed for?
The technology is designed for patients with severe neurological conditions including ALS, stroke, and spinal cord injury that result in paralysis or loss of communication, as well as future applications for mental health conditions.
